ORIGINAL RESEARCH SCN5A Genetic Polymorphisms Associated With Increased Deﬁbrillator Shocks Brugada Syndrome Pattarapong Makarawate MD FHRS Narumol Chaosuwannakit MD Suda Vannaprasaht MD Dujdao Sahasthas MD Seok Hwee Koo PhD Edmund Jon Deoon Lee MD PhD Wichittra Tassaneeyakul PhD Hector BarajasMartinez PhD FHRS Dan Hu MD PhD FAHA FACC FHRS Kittisak Sawanyawisuth MD PhD BackgroundBrugada syndrome BrS inherited primary arrhythmia disorder leading sudden cardiac arrest SCN5A encoding asubunit cardiac sodium channel Nav15 common pathogenic gene BrS An implantable cardioverter deﬁbrillator ICD standard treatment secondary prevention This study aimed evaluate association SCN5A variant cardiac conduction disturbance appropriate ICD shock therapy Thai symptomatic BrS patients ICD implants Methods ResultsSymptomatic BrS patients diagnosed university hospital enrolled 2008 2011 The primary outcome study appropriate ICD shock deﬁned having nonpacingassociated ICD shock occurrence ventricular tachycardia ventricular ﬁbrillation Associations SCN5A polymorphisms cardiac conduction disturbance potential confounding factors associated appropriate ICD shock therapy analyzed All 40 symptomatic BrS patients median age 43 years ICD implantations followed 24 months There 16 patients 40 appropriate ICD shock therapy ICD treatment An independent factor associated appropriate ICD shock therapy SCN5AR1193Q adjusted hazard ratio 10550 95 CI 163168232 ConclusionsSCN5AR1193Q associated cardiac conduction disturbances It genetic marker associated ventricular arrhythmia leading appropriate ICD shock therapy symptomatic BrS patients ICD treatment Because small sample size study population appropriate ICD shock outcome large studies needed conﬁrm results study J Am Heart Assoc 20176e005009 DOI 101161JAHA116005009 Key Words appropriate implantable cardioverter deﬁbrillator shock therapy cid129 Brugada syndrome cid129 genetics cid129 implantable cardioverter deﬁbrillator cid129 SCN5A R1193Q B rugada syndrome BrS diagnosed patients STsegment elevation type 1 morphology 2 mm 1 lead right precordial From Departments Medicine PM DS KS Radiology NC Pharmacology SV WT Faculty Medicine Research Center Back Neck Other Joint Pain Human Performance BNOJPH Sleep Apnea Research Group KS Khon Kaen University Khon Kaen Thailand NUS Pharmacogenetics Laboratory Department Pharmacology National Univer sity Singapore Singapore SHK EJDL Clinical Trials Research Unit Changi General Hospital Singapore SHK Molecular Genetic Department Masonic Medical Research Laboratory Utica NY HBM DH Department Cardiology Cardiovascular Research Institute Renmin Hospital Wuhan University Wuhan University Wuhan China DH Dr Hu Dr Sawanyawisuth contributed equally work colast authors Correspondence Kittisak Sawanyawisuth MD PhD Department Medicine Faculty Medicine Khon Kaen University Khon Kaen 40002 Thailand Email kittisakkkuacth Received December 5 2016 accepted April 12 2017 ª 2017 The Authors Published behalf American Heart Association Inc Wiley This open access article terms Creative Commons AttributionNonCommercialNoDerivs License permits use distribution medium provided original work properly cited use noncommercial modiﬁcations adaptations leads V1 andor V2 positioned second fourth intercostal spaces occurring spontaneously provocative drug testing intravenous administration sodiumchannel blockers12 In Thailand survivors sudden cardiac arrest SCA ECG proﬁle symptoms characteristic BrS documented family history SCA34 Most patients young born raised northeastern Thailand previous medical history It believed BrS inherited disease attributed genetic penetrance family members Currently implantable car dioverter deﬁbrillator ICD standard treatment secondary prevention postSCA syncope unknown origin56 The ICD effective treatment prevent cardiac arrest recurrent ventricular tachycardia ventricular ﬁbrillation VF BrS patients The SCN5A gene mutations 20 25 BrS patients 0 008 general population1 There 4 known common polymorphisms SCN5A gene related BrS including R34C H558R S1103Y R1193Q78 These SCN5A polymorphisms decrease DOI 101161JAHA116005009 Journal American Heart Association 1 R1193Q BrS Makarawate et al Clinical Perspective What New cid129 SCN5AR1193Q genetic marker associated cardiac conduction defects ventricular ﬁbrillation symp tomatic BrS patients What Clinical Implications cid129 Cardiologists aware BrS patients SCN5AR1193Q polymorphism require careful monitoring medications electrolyte abnormalities prevent ventricular arrhythmias expression sodiumchannel proteins alter gating properties resulting prolongation QRS duration slow conduction heart79 The SCN5A mutations associated early frequent VF recurrence SCA BrS patients related ﬁbrosis right ventricular outﬂow tract epicardial surface1011 Most studies SCN5A mutations included asymptomatic symptomatic BrS patients811 This study aimed investigate association SCN5A mutations appro priate ICD shock therapy symptomatic BrS patients Methods Study Population All patients diagnosed BrS Queen Sirikit Heart Center The Northeast Srinagarind Hospital Khon Kaen University Thailand 2008 2011 enrolled The diagnosis BrS clinically patients present ing SCA unexplained syncope 1 following criteria evidence documented ventricular tachycardia VF family history sudden cardiac death 45 years age similar type ECG family members history nocturnal agonal respiration spontaneous type 1 Brugada ECG showing type 1 Brugada ECG provocation high intercostal ECG lead detection adminis tration ﬂecainide Type 1 ECG deﬁned prominent coved ST segment elevation 2 mm followed negative T wave2 All patients received cardiac workups including echocar diograms coronary angiograms exclude structural heart diseases All workups structural heart disease required normal The study protocol approved institutional review committee Khon Kaen University conformed Declaration Helsinki All patients provided informed consent study enrollment The following clinical data captured documented age diagnosis sex birthplace family history SCA type O R I G I N A L R E S E A R C H Brugada ECG diagnosis results pharmacological testing high intercostal lead detection unmasking coved type ECG pattern circumstances diagnosis survival SCA syncope indication ICD implantation genetic study SCN5A genotyping ICD followup data High intercostal ECGs obtained placing precordial V1 V2 leads fourth intercostal space V3 V4 intercostal space V5 V6 second intercostal space V1 V3 V5 placed right V2 V4 V6 left The diagnosis BrS high evidence covedtype ECG intercostal leads12 1 SCN5A Genotyping Ten milliliters peripheral venous blood obtained patients standard blood sampling techniques Genomic DNA patient isolated peripheral leukocytes All 28 exons SCN5A determined amplifying speciﬁc primers13 The polymerase chain reaction products sequenced BigDye Terminator v31 Cycle Sequencing Kit run automated ABI Prism Model 3100 Avant Genetic Analyzer Applied Biosystems Foster City CA Outcomes All patients followed cardiac device clinic 3 6 months ICD data patient collected interpreted followup All patients categorized BrS recurrent appropriate ICD shock Appro priate ICD shock deﬁned having nonpacingassociated ICD shock occurrence ventricular tachycardia VF14 Those patients inappropriate ICD shocks sinus tachycardia atrial ﬁbrillation lead fractures excluded Statistical Analysis The Wilcoxon ranksum test comparison medians continuous variables BrS patients appropriate shock Fishers exact test compare categorical variables 2 groups Univariate Cox regression analysis applied calculate individual variables having crude hazard ratios appropriate ICD shocks times All variables P020 univariate analysis clinically signiﬁcant included subsequent multivariate Cox regression analysis Clinically signiﬁcant factors previously reported potential confounding factors associated appropriate ICD shock family history SCA The ﬁnal model composed potential confounding factors associated appropriate DOI 101161JAHA116005009 Journal American Heart Association 2 R1193Q BrS Makarawate et al ICD shock follows family history cardiac arrest PR interval QRS duration SCN5AR1193Q Analytical results presented adjusted hazard ratios 95 CIs The signiﬁcant factors plotted ICD shockfree times time ﬁrst ICD shock KaplanMeier analysis Results During study period 40 patients met study inclusion criteria received singlechamber ICD treatment pro gramed VF zone 188 beatsmin The median range age patients 43 years 2266 The median range followup time 24 months 1352 There 29 patients 725 spontaneous Brugada ECG type 1 11 patients 275 unmasked high inter costal lead placement Of 28 exons SCN5A genotyping H558R Exon12 c 1673 AG rs1805124 R1193Q Exon 20 c3578GA rs41261344 identiﬁed 9 225 6 150 patients allele frequencies 0113 0075 The HardyWeinberg equilibrium tested check included individuals equilibrium frequencies genotype The genotypes 2 singlenucleotide poly morphisms SCN5A H558R R1193Q followed HardyWeinberg equilibrium implies included individuals likely represent population Among 16 patients 40 appropriate ICD shock therapy ICD treatment 10 patients history SCA The average time ﬁrst ICD shock 850cid1443 months Almost patients male 975 SCA common indication ICD treatment 725 A signiﬁcantly higher percentage patients SCN5AR1193Q observed group appropriate ICD shock 3125 versus 435 P0029 However frequency patients carried SCN5A H558R signiﬁcantly different 2 groups shown Table 1 Of 40 eligible symptomatic BrS patients 9 225 SCN5AH558R andor R1193Q Two 5 BrS patients SCN5AH558R R1193Q 7 18 4 10 BrS patients SCN5AH558R R1193Q Table 1 The association SCN5A polymor phisms electrocardiographic ﬁndings shown Tables 2 4 SCN5AR1193Q associated longer PR interval 201 196212 versus 168 162176 ms P0002 widening QRS duration 145 140155 versus 133 128142 ms P0023 shown Table 3 Figure 1 Four potential confounding factors included Cox proportional model identify factors associated appropriate ICD therapy including family history cardiac arrest PR interval QRS duration SCN5AR1193Q O R I G I N A L R E S E A R C H Table 1 Characteristics Symptomatic BrS Patients Treated With ICD Categorized Occurrence Recurrent ICD Shock Factors Median age range y No ICD Shock n24 45 2260 ICD Shock n16 43 3166 Male sex 23 9583 16 100 Sudden cardiac arrest 16 6667 13 8125 Family history sudden 7 2917 7 4375 P Value 0934 0999 0473 0343 death Spontaneuos Brugada 16 6667 13 8125 0312 ECG type 1 Median PR interval ms QRS duration ms SCN5A genotype H558R R1193Q H558RR1193Q H558RR1193Qcid3 H558Rcid3R1193Q H558Rcid3R1193Qcid3 167 148224 134 100152 177 154220 139 124162 0082 0292 5 2083 1 435 1 417 4 1667 0 19 7917 4 2500 5 3125 1 625 3 1875 4 2500 8 5000 0999 0029 0999 0999 0020 0086 Data presented number percentage indicated H558R patients carried mutation 558 H R R1193Q patients carried mutation 1193 R Q H558RR1193Qcid3 patients carried mutation 558 H R mutation 1193 H558Rcid3R1193Q patients carried mutation 1193 R Q mutation 558 H558Rcid3R1193Qcid3 patients mutation positions ICD indicates implantable cardioverter deﬁbrillator shown Table 5 Unadjusted hazard ratio SCN5A R1193Q highest 10629 Table 5 For multi variate model SCN5AR1193Q signiﬁcantly asso ciated appropriate ICD shock therapy symptomatic BrS patients received ICD treatment secondary prevention adjusted hazard ratio 10550 95 CI 163168232 Those patients positive SCN5A R1193Q shorter times ICD shockfree time compared patients negative SCN5A R1193Q Figure 2 Table 2 Association Between SCN5A Polymorphism Electrocardiographic Findings PR interval ms QRS duration ms SCN5A n9 190 188194 142 138146 SCN5Acid3 n31 166 162176 132 128142 P Value 0006 0017 Positive SCN5A indicated presence H558R andor R1193Q Data presented median 25th quartile 75th quartile DOI 101161JAHA116005009 Journal American Heart Association 3 R1193Q BrS Makarawate et al Table 3 Association Between R1193Q Electrocardio graphic Findings PR interval ms QRS duration ms R1193Q N4 201 196212 145 140155 R1193Qcid3 N34 168 162176 133 128142 P Value 0002 0023 Data presented median 25th quartile 75th quartile Discussion Only 2 known SCN5A polymorphisms identiﬁed 40 symptomatic BrS patientsH558R R1193Q 9 225 6 150 patients allele frequencies 0113 0075 As previous report global frequency R1193Q OMIM 6001630023 00124 R1193Q Asian Chinese 005008 Viet namese 008 Japanese 002 deﬁned mutation populations white 000 black 000 The frequency R1193Q study higher Thai general population 0075 versus 00395 symptomatic BrS cases majority history SCA included present study15 Moreover R1193Q present study associated cardiac conduction delay evidence longer PR wider QRS duration signiﬁcantly higher frequency R1193Q observed BrS patients receiving appro priate ICD shock therapy receive ICD shock therapy 3125 versus 435 P0029 shown Table 1 Ohkubo et al reported prolonged QRS duration 120 ms measured standard ECG associated lifethreatening ventricular arrhythmia BrS9 These ﬁndings occur abnormal slow fragmented epicardial electrograms reduction gap junction expression right ventricular outﬂow tract evidenced autopsies11 These abnormal electrograms caused cardiac conduction delay lead generate reentry ventricular arrhythmia shown study appropriate ICD therapy BrS patients Table 1 This study conﬁrms importance QRS duration risk ventricular arrhythmia Table 4 Association Between H558R Electrocardio graphic Findings Factors PR interval ms QRS duration ms H558R n7 188 168192 140 138144 H558Rcid3 n31 166 162176 132 128142 P Value 0042 0082 Data presented median 25th quartile 75th quartile O R I G I N A L R E S E A R C H Previous reports showed R1193Q polymorphism accelerate inactivation sodiumchannel current leading cardiac conduction defect endocar dial epicardial repolarization abnormalities resulting arrhythmogenesis1618 The PR prolongation differenti ate SCN5A nonSCN5A BrS patients1920 The study showed longer PR intervals BrS patients R1193Q H558R SCN5A polymorphisms Tables 2 4 This study shows rate appropriate ICD therapy 345 aborted SCA group These rates comparable previous study reported discharge rates appropriate ICD therapy 44 aborted SCA group 7year followup period21 Forty symptomatic BrS patients receiving ICD treatment examined study R1193Q factor associated appropriate ICD shock therapy ICD treatment univariate multivariate Cox regression survival analysis Table 5 This ﬁnding explained genetic heterogeneous character BrS different ethnici ties R1193Q associated cardiac conduction delays leading modulate arrhythmogenic substrates ventricular arrhythmia recurrent appropriate ICD ther apy22 R1193Q G A mutation position 3578 causes substitution arginine glutamine position 1193 appeared genetic factor associated appropriate ICD shock therapy symptomatic BrS patients ICD treatment Therefore cardiologists carefully follow awareness recurrent ventricular tachycardia VF symptomatic BrS patients polymorphism avoiding modulating factors psychotropic drugs fever class I antiarrhythmic drugs electrolyte abnormal ities23 H558R A G mutation position 1673 causes substitution histidine arginine position 558 associated sodiumchannel inactivation strong R1193Q24 The results study supported hypothesis evidenced prolongation PR interval signiﬁcant QRS widening BrS patients presence H558R Table 4 And H558R associated appropriate ICD shocks symptomatic BrS patients Table 1 The family history SCA proposed 1 risk predictor past4 Recent evidence clearly demonstrated family history reliable marker high risk patients affected BrS2 Moreover value family history sudden death BrS patients extensively investigated results family history SCA predictive future arrhythmic events2526 Consistent studies present results family history SCA shown DOI 101161JAHA116005009 Journal American Heart Association 4 O R I G I N A L R E S E A R C H R1193Q BrS Makarawate et al A B C Figure 1 ECGs SCN5AR1193Q carrier recurrent ventricular ﬁbrillation VF appropriate implantable cardioverter deﬁbrillator ICD treatment A ECG shows widening QRS duration 152 ms prolongation PR interval 200 ms B ICD record appropriate VF detection C Successful ICD shock VF associated recurrent ICD shocks Thai symptomatic BrS BrS uncommon genetic disease resulting small sample size Presence R1193Q polymorphism categorical data Because small study populations categorical data CI R1193Q polymorphism large This study relatively isolated population patients originally northeastern Thailand ﬁndings inferred populations Another limitation study 2 polymorphisms SCN5A identiﬁed study If BrS patients mutations addition R1193Q risks ventricular arrhythmias higher Table 5 Factors Associated With Appropriate ICD Shock Therapy Symptomatic BrS Patients Factors Family history cardiac arrest PR interval QRS duration SCN5AR1193Q Unadjusted Hazard Ratio 95 CI 1290 04283891 Adjusted Hazard Ratio 95 CI 1054 02714098 1015 09881043 1027 09771081 10629 180762508 0980 08881081 1058 08811271 10550 163168232 ICD indicates implantable cardioverter deﬁbrillator DOI 101161JAHA116005009 Journal American Heart Association 5 R1193Q BrS Makarawate et al Figure 2 KaplanMeier survival curve symptomatic Brugada Syndrome patients treated implantable cardioverter deﬁbrillator ICD showed probabilities ICD shock free time ﬁrst ICD shock categorized presence R1193Q polymorphism Further large studies needed conﬁrm results study But strength uniqueness study patients enrolled study symptomatic BrS patients documented SCA In study diagnosis BrS clinically We retrospectively traced patients study 2016 diagnostic criteria BrS27 All patients met deﬁnite criteria BrS median Shanghai score 65 range 4075 In conclusion SCN5AR1193Q polymorphism associated cardiac conduction disturbance genetic factor associated ventricular arrhythmia leading appropriate ICD shock therapy symptomatic BrS patients ICD treatment This study needed conﬁrmed ethnicities larger sample size future Acknowledgments The authors like thank James A Will Wisconsin USA Publication Clinic KKU Thailand University kind manuscript English editing Sources Funding IRG 5780016 TRF The Thailand Research Fund TRF Senior Research Scholar Grant Thailand Research Fund TRF Grant No RTA5880001 Higher Education Research Promotion National Research University Project Thailand Ofﬁce Higher Education Commission Thailand Health Cluster SHePGMS Khon Kaen University grant Faculty Medicine Khon Kaen University Thailand Grant No RG59301 O R I G I N A L R E S E A R C H Disclosures None References 1 Priori SG Wilde AA Horie M Cho Y Behr ER Berul C Blom N Brugada J Chiang CE Huikuri H Kannankeril P Krahn A Leenhardt A Moss A Schwartz PJ Shimizu W Tomaselli G Tracy C HRSEHRAAPHRS expert consensus statement diagnosis management patients inherited primary arrhythmia syndromes document endorsed HRS EHRA APHRS May 2013 ACCF AHA PACES AEPC June 2013 Heart Rhythm 20131019321963 2 Berne P Brugada J Brugada syndrome 2012 Circ J 20127615631571 3 Nademanee K Veerakul G Nimmannit S Chaowakul V Bhuripanyo K Likittanasombat K Tunsanga K Kuasirikul S Malasit P Tansupasawadikul S Tatsanavivat P Arrhythmogenic marker sudden unexplained death syndrome Thai men Circulation 19979625952600 4 Tatsanavivat P Chirawatkul A Klungboonkrong V Chaisiri S Jarerntanyaruk L Munger RG Saowakontha S Sudden unexplained deaths sleep Lai Tai young men rural northeastern Thailand Int J Epidemiol 199221904 910 5 Brugada J Brugada R Brugada P Pharmacological device approach therapy inherited cardiac disease associated cardiac arrhythmias sudden death J Electrocardiol 2000334147 6 Nademanee K Veerakul G Mower M Likittanasombat K Krittayapong R Bhuripanyo K Sitthisook S Chaothawee L Lai MY Azen SP Deﬁbrillator versus beta blockers unexplained death Thailand DEBUT randomized clinical trial Circulation 200310722212226 7 Ackerman M Splawski I Makielski J Tester DJ Will ML Timothy KW Keating MT Jones G Chadha M Burrow CR Stephens JC Xu C Judson R Curran ME Spectrum prevalence cardiac sodium channel variants black white Asian Hispanic individuals implication arrhythmogenic suscep tibility Brugadalong QT syndrome genetic testing Heart Rhythm 20045600607 8 Kapplinger JD Tester DJ Alders M Benito B Berthet M Brugada J Brugada P Fressart V Guerchicoff A HarrisKerr C Kamakura S Kyndt F Koopmann TT Miyamoto Y Pfeiffer R Pollevick GD Probst V Zumhagen S Vatta M Towbin JA Shimizu W SchulzeBahr E Antzelevitch C Salisbury BA Guicheney P Wilde AA Brugada R Schott JJ Ackerman MJ An international compendium mutations SCN5A encoded cardiac sodium channel patients referred Brugada syndrome genetic testing Heart Rhythm 201073346 9 Ohkubo K Watanabe I Okumura Y Ashino S Kofune M Nagashima K Kofune T Nakai T Kunimoto S Kasamaki Y Hirayama A Prolonged QRS duration lead V2 risk lifethreatening ventricular arrhythmia patients Brugada syndrome Int Heart J 20115298102 10 Nishii N Ogawa M Morita H Nakamura K Banba K Miura D Kumagai N Matsunaga A Kawamura H Urakawa S Miyaji K Nagai M Satoh K Nakagawa K Tanaka M Hiramatsu S Tada T Murakami M Nagase S Kohno K Kusano Ito H SCN5A mutation associated early KF Saku K Ohe T recurrence ventricular ﬁbrillation patients Brugada frequent syndrome Circ J 20107425722578 11 Nademanee K Raju H Noronha SV Papadakis M Robinson L Rothery S Makita N Kowase S Boonmee N Vitayakritsirikul V Ratanarapee S Sharma S van der Wal AC Christiansen M Tan HL Wilde AA Nogami A Sheppard MN Veerakul G Behr ER Fibrosis connexin43 conduction abnormalities Brugada syndrome J Am Coll Cardiol 20156619761986 12 Sangwatanaroj S Prechawat S Sunsaneewitayakul B Sitthisook S Tosukho wong P Tungsanga K New electrocardiographic leads procainamide test detection Brugada sign sudden unexplained death syndrome survivors relatives Eur Heart J 20012222902296 13 Koo SH Teo WS Ching CK Chan SH Lee EJ Mutation screening KCNQ1 HERG KCNE1 KCNE2 SCN5A genes long QT syndrome family Ann Acad Med Singapore 200736394398 14 Sweeney MO Ruetz LL Belk P Mullen TJ Johnson JW Sheldon T Bradycardia onset ventricular pacinginduced shortlongshort sequences tachyarrhythmias possible mechanism proarrhythmia J Am Coll Cardiol 200750614622 15 Matsusue A Yuasa I Umetsu K Nakayashiki N Dewa K Nishimukai H Kashiwagi M Hara K Waters B Takayama M Ikematsu N Kubo S The global distribution pR1193Q polymorphism SCN5A gene Leg Med Tokyo 2016197276 16 Matsusue A Kashiwagi M Hara K Waters B Sugimura T Kubo S An autopsy case sudden unexpected nocturnal death syndrome R1193Q polymorphism SCN5A gene Leg Med Tokyo 201214317319 DOI 101161JAHA116005009 Journal American Heart Association 6 R1193Q BrS Makarawate et al 17 Huang H Zhao J Barrane FZ Champagne J Chahine M Nav15R1193Q polymorphism associated long QT Brugada syndromes Can J Cardiol 200622309313 18 Probst V Allouis M Sacher F Pattier S Babuty D Mabo P Mansourati J Victor J Nguyen JM Schott JJ Boisseau P Escande D Le Marec H Progressive cardiac conduction defect prevailing phenotype carriers Brugada syndrome SCN5A mutation J Cardiovasc Electrophysiol 200617270275 19 Smits JP Eckardt L Probst V Bezzina CR Schott JJ Remme CA Haverkamp W Breithardt G Escande D SchulzeBahr E LeMarec H Wilde AA Genotype phenotype relationship Brugada syndrome electrocardiographic features differentiate SCN5Arelated patients nonSCN5Arelated patients J Am Coll Cardiol 200240350356 20 Gehi AK Duong TD Metz LD Gomes JA Mehta D Risk stratiﬁcation individuals Brugada electrocardiogram metaanalysis J Cardiovasc Electrophysiol 200617577583 21 Conte G Sieira J Ciconte G Asmundis C Chierchia GB Baltogiannis G Di Giovanni G La Meir M Wellens F Czapla J Wauters K Levinstein M Saitoh Y Irfan G Julicid1a J Pappaert G Brugada P A 20 year single center experience Implantable cardioverterdeﬁbrillator therapy Brugada syndrome 20year singlecenter experience J Am Coll Cardiol 201565879888 22 Probst V Wilde AA Barc J Sacher F Babuty D Mabo P Mansourati J Le Scouarnec S Kyndt F Le Caignec C Guicheney P Gouas L Albuisson J Meregalli PG Le Marec H Tan HL Schott JJ SCN5A mutations role genetic background pathophysiology Brugada syndrome Circ Cardiovasc Genet 20092552557 23 Sacher F Probst V Iesaka Y Jacon P Laborderie J MizonGcid3erard F Mabo P Reuter S Lamaison D Takahashi Y ONeill MD Garrigue S Pierre B Jaıs P Pasquicid3e JL Hocini M SalvadorMazenq M Nogami A Amiel A Defaye P Bordachar P Boveda S Maury P Klug D Babuty D Haıssaguerre M Mansourati J Clcid3ementy J Le Marec H Outcome implantation cardioverterdeﬁbrillator patients Brugada syndrome multicenter study Circulation 200611423172324 24 Poelzing S Forleo C Samodell M Dudash L Sorrentino S Anaclerio M Troccoli R Iacoviello M Romito R Guida P Chahine M Pitzalis M Deschenes I SCN5A polymorphism restores trafﬁcking Brugada syndrome mutation separate gene Circulation 2006114368376 O R I G I N A L R E S E A R C H 25 Priori SG Gasparini M Napolitano C Della Bella P Ottonelli AG Sassone B Giordano U Pappone C Mascioli G Rossetti G De Nardis R Colombo M Risk stratiﬁcation Brugada syndrome results PRELUDE PRogrammed J Am Coll Cardiol ELectrical 2012593745 stimUlation preDictive valuE registry 26 Sarkozy A Sorgente A Boussy T Casado R Paparella G Capulzini L Chierchia GB Yazaki Y De Asmundis C Coomans D Brugada J Brugada P The value family history sudden death patients diagnostic type I Brugada ECG pattern Eur Heart J 20113221532160 27 Antzelevitch C Yan GX Ackerman MJ Borggrefe M Corrado D Guo J Gussak I Hasdemir C Horie M Huikuri H Ma C Morita H Nam GB Sacher F Shimizu W Viskin S Wilde AA Jwave syndromes expert consensus conference report emerging concepts gaps knowledge Heart Rhythm 201613e295 e324 DOI 101161JAHA116005009 Journal American Heart Association 7